DEFENSIN THERAPEUTICS ApS: Financial statements 2025
CVR: 35513280
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
DEFENSIN THERAPEUTICS ApS (CVR 35513280) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437. The solvency ratio was 79.5%.
- Gross Profit
- DKK -538,913
- Profit/Loss
- DKK -539,063
- Equity
- DKK 774,437
- Total Assets
- DKK 973,982
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -539K | -539K | 774K | 0 |
| 2024 | - | - | -131K | 1.3M | - |
| 2023 | - | - | -425K | 1.4M | - |
| 2022 | - | - | -474K | 1.7M | - |
| 2021 | 0 | - | -366K | 2.1M | - |
Official annual report
How creditworthy is DEFENSIN THERAPEUTICS ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
DEFENSIN THERAPEUTICS ApS has published its annual report for 2024. The net result was DKK -130,534.
As of June 19, 2025, EY Godkendt Revisionspartnerselskab has stepped down as auditor of DEFENSIN THERAPEUTICS ApS.
About DEFENSIN THERAPEUTICS ApS
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.